Drug Profile
SPRC AB01
Alternative Names: SPRC-AB01; Sybryx; Tobramycin solution for nasal inhalationLatest Information Update: 11 Sep 2013
Price :
$50
*
At a glance
- Originator Naryx Pharma
- Class Aminoglycosides; Antibacterials; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Sinusitis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 11 Sep 2013 Discontinued - Phase-II for Sinusitis in USA (Inhalation)
- 27 Nov 2007 Naryx Pharma completed enrolment into its phase IIb trial for chronic sinusitis in USA